(Billing Code: ) DEPARTMENT OF HEALTH AND HUMAN SERVICES. Office of the Secretary. Findings of Research Misconduct

Similar documents
(Billing Code: ) DEPARTMENT OF HEALTH AND HUMAN SERVICES. Office of the Secretary. Findings of Research Misconduct

[Billing Code: ] DEPARTMENT OF HEALTH AND HUMAN SERVICES. Office of the Secretary. Findings of Research Misconduct

Billing Code: P DEPARTMENT OF HEALTH AND HUMAN SERVICES. Centers for Disease Control and Prevention. [30Day-18-17AUZ]

Centers for Disease Control and Prevention. Recommendations for Providers Counseling Male Patients and

Statement of Organization, Functions, and Delegations of Authority. Part C (Centers for Disease Control and Prevention) of the Statement of

Agency Information Collection Activities: Proposed Collection; Comment Request

DEPARTMENT OF HEALTH AND HUMAN SERVICES. Health Resources and Service Administration. Women's Preventive Services Guidelines

Agency Forms Undergoing Paperwork Reduction Act Review. In accordance with the Paperwork Reduction Act of 1995, the

Billing Code: P DEPARTMENT OF HEALTH AND HUMAN SERVICES. Centers for Disease Control and Prevention. [30Day-16-15BBT]

Proposed Data Collection Submitted for Public Comment and. AGENCY: Centers for Disease Control and Prevention (CDC),

DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Healthcare Research and Quality

DEPARTMENT OF VETERANS AFFAIRS SUMMARY: The Department of Veterans Affairs (VA) is amending its medical

Centers for Disease Control and Prevention. Final Revised Vaccine Information Materials for MMR

World Trade Center Health Program; Petition 006 Primary Biliary

Centers for Disease Control and Prevention. CDC Sex-Specific Body Mass Index (BMI)-For-Age Growth Charts

Billing Code: P DEPARTMENT OF HEALTH AND HUMAN SERVICES. Centers for Disease Control and Prevention. [30Day ]

SUMMARY Provides for the award of certain grants relating to the prevention and treatment

Centers for Disease Control and Prevention. Proposed Revised Vaccine Information Materials for MMR

Establishment of a New Drug Code for Marihuana Extract. AGENCY: Drug Enforcement Administration, Department of Justice.

Proposed Data Collection Submitted for Public Comment and. AGENCY: Centers for Disease Control and Prevention (CDC),

Stephen C. Joseph, M.D., M.P.H.

Ted Yeshion, Ph.D. Science Subcommittee Chair Professor of Forensic Science Edinboro University of Pennsylvania

Case Studies in Research Misconduct. Tony Onofrietti, M.S., CRSS

SUMMARY: The Food and Drug Administration (FDA) is requesting public input on updated

DEPARTMENT OF VETERANS AFFAIRS SUMMARY: The Department of Veterans Affairs (VA) proposes to amend its medical

Human Resources All Personnel BP 4020 DRUG AND ALCOHOL-FREE WORKPLACE

Los Angeles County Pioneers in Tobacco Control Smoking Cessation Project

Agency Information Collection Activities; Submission for Office of Management and Budget

STATE OF NEW JERSEY DEPARTMENT OF CORRECTIONS. Medication Assisted Treatment For Substance Use Disorder In the New Jersey County Jails

Generic Drug User Fee Amendments of 2012; Regulatory Science Initiatives; Public Hearing;

SUMMARY: This document announces the renewal of 17 substances on the National List of

Agency Information Collection Activities; Submission for Office of Management and

Schedules of Controlled Substances: Temporary Placement of Furanyl Fentanyl. AGENCY: Drug Enforcement Administration, Department of Justice

Three-Month Extension of Certain Tobacco Product Compliance Deadlines Related to the

Implementation of the Stem Cell Therapeutic and Research Act of 2005

Clinical Chemistry and Clinical Toxicology Devices Panel of the Medical Devices Advisory

LOS ANGELES UNIFIED SCHOOL DISTRICT Policy Bulletin

Human Research Protection Program Institutional Review Board Procedure

VERIFICATION OF VOLUNTARY DONATION FOR HUMAN EMBRYONIC STEM CELL RESEARCH

Notice of Request for Extension of Approval of an Information Collection; Swine Health. AGENCY: Animal and Plant Health Inspection Service, USDA.

Act 443 of 2009 House Bill 1379

Proposed Data Collection Submitted for Public Comment and. AGENCY: Centers for Disease Control and Prevention (CDC),

COOPERATIVE AGREEMENTS FOR STATE-BASED COMPREHENSIVE BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAMS

National Organic Program (NOP); Sunset 2017 Amendments to the National List

NOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN

National Vaccine Injury Compensation Program: Adding the Category of Vaccines. AGENCY: Health Resources and Services Administration (HRSA), HHS.

NOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN (NIDPOE)

DEPARTMENT OF TRANSPORTATION. National Highway Traffic Safety Administration. [Docket Number: NHTSA ]

Highly Concentrated Caffeine in Dietary Supplements; Guidance for Industry; Availability

Schedules of Controlled Substances: Placement of Furanyl fentanyl, 4- Fluoroisobutyryl fentanyl, Acryl fentanyl, Tetrahydrofuranyl fentanyl, and

Patient-Focused Drug Development Public Meeting on Chagas Disease

S Congenital Heart Futures Act (Introduced in Senate - IS) 111th CONGRESS 1st Session S. 621 IN THE SENATE OF THE UNITED STATES.

Over-the-Counter Pediatric Liquid Drug Products Containing Acetaminophen

SUMMARY: We are amending the fruits and vegetables regulations to allow the importation of

DEPARTMENT OF TRANSPORTATION. [Docket Numbers FMCSA and FRA ]

Certification in Lower Extremity Geriatric Medicine Handbook

Proposed Data Collection Submitted for Public Comment and. AGENCY: Centers for Disease Control and Prevention (CDC),

NOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN (NIDPOE)

Recognizing European Union (EU) and EU Member State Regionalization Decisions for African

ANDA Arthur P. Bedrosian, President Armenpharm, Ltd. 49 South Ridge Road P.O. Box D1400 Pomona, NY December 3, 2015

Proposed Data Collection Submitted for Public Comment and. AGENCY: Centers for Disease Control and Prevention (CDC),

Patricia Ward Chief Budget Officer (919)

PROPOSED REGULATION OF THE BOARD OF HEARING AID SPECIALISTS. LCB File No. R July 6, 2001

Medicare, Medicaid, and Children's Health Insurance Programs: Announcement of the

Billing Code: P DEPARTMENT OF HEALTH AND HUMAN SERVICES. Centers for Disease Control and Prevention. [60Day-12-12MW]

Flavored Milk; Petition to Amend the Standard of Identity for Milk and 17 Additional Dairy

CHAPTER Section 3 of P.L.1983, c.296 (C.45: ) is amended to read as follows:

Agency Information Collection Activities; Submission for Office of Management and

The Oncofertility Consortium : Policy and Guidelines Statement

DISCIPLINE COMMITTEE OF THE COLLEGE OF PHYSIOTHERAPISTS OF ONTARIO COLLEGE OF PHYSIOTHERAPISTS OF ONTA RIO. - and

OHRP Guidance on the Involvement of Prisoners in Research

Dear Applicant for Sober Living Environment Registration,

Guidance for Industry

H 5501 S T A T E O F R H O D E I S L A N D

Medicare, Medicaid, and Children's Health Insurance Programs: Announcement of the

11/9/2016. Therapeutic Misconception and the Clinical Investigator. Beyond Protocol Deviations

Chapter TOBACCO RETAILER'S PERMIT

Regulation of the Chancellor

Cancer Immunotherapy Pilot Program/ Patents 4 Patients. USPTO BCP Customer Partnership Meeting Alexandria, VA August 2, 2017

Barr Laboratories, Inc. et al.; Withdrawal of Approval of 68 Abbreviated New Drug Applications

Food Additives Permitted for Direct Addition to Food for Human Consumption; Vitamin D 2

DEPARTMENT OF HEALTH AND HUMAN SERVICES Agency for Healthcare Research and Quality

Mini Summit XIV: Clinical Trial Disclosure and Results Reporting Liability under FDAAA, Section 801

SENATE, No STATE OF NEW JERSEY. 218th LEGISLATURE INTRODUCED FEBRUARY 5, 2018

Alaska House Finance Committee October 31, 2017

ENVIRONMENTAL PROTECTION AGENCY 40 CFR Parts 9, 22, 85, 86, 600, 1033, 1036, 1037, 1039, 1042, 1065, 1066, and 1068

Enhanced Comprehensive HIV Prevention Planning (ECHPP) Project Overview

SEXUAL HARASSMENT POLICY

Controlling the Progression of Myopia: Contact Lenses and Future Medical Devices; Public

ACTION: Notification; declaratory order; extension of compliance date.

SUMMARY: Before a Federal agency can collect certain information from the public, it must

A resident's salary will continue, during the time they are exercising the Grievance Procedure rights, by requesting and proceeding with a hearing.

Nanda Gudderra, M. Sc., M.S., Ph.D. Associate VP for Research Northern Arizona University Web: research.nau.edu/compliance

<AGENCY TYPE='S'>DEPARTMENT OF HEALTH AND HUMAN SERVICES. <SUBJECT>New Animal Drugs; Hyaluronate Sodium; Hydrogen Peroxide; Imidacloprid and

Oral Health Provisions in Recent Health Reform: Opportunities for Public-Private Partnerships

A mandatory pre-proposal meeting will be held on Tuesday, July 9, 2013 at 1:00 p.m. at the City Hall Multi Purpose Room.

SOLANO COMMUNITY COLLEGE DISTRICT SMOKING ON CAMPUS 4215

As Passed by the Senate. Regular Session Sub. H. B. No

Authorship Guidelines for CAES Faculty Collaborating with Students

Transcription:

This document is scheduled to be published in the Federal Register on 06/08/2016 and available online at http://federalregister.gov/a/2016-13541, and on FDsys.gov (Billing Code: 4150-31) DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct AGENCY: Office of the Secretary, HHS ACTION: Notice. SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Meredyth M. Forbes, Albert Einstein College of Medicine: Based on an assessment conducted by the Albert Einstein College of Medicine (AECM), an admission from the Respondent, and additional analysis conducted by ORI in its oversight review, ORI found that Ms. Meredyth M. Forbes, former Graduate Student, AECM, engaged in research misconduct in research supported by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH), grants R01 GM089979, T32 GM007491, R01 GM55101, and R01 GM88202 and National Institute of Child Health and Human Development (NICHD), NIH, grant T32 HD007502. ORI found that Respondent engaged in research misconduct by intentionally falsifying and/or fabricating data reported in the following three (3) published papers and four (4) meeting presentations: 1

$ Development. In press, published online, Dec 23, 2015; doi:10.1242/dev.129023 (hereafter referred to as the December 2015 Development paper ) $ Cell Reports 12:49-57, 2015 (hereafter referred to as the Cell Reports paper ) $ Development 142(15):2704-18, 2015 Aug 1 (hereafter referred to as the August 2015 Development paper ) $ Maternal dazap2 regulates germ granules via counteracting Dynein in zebrafish primordial germ cells. Laboratory Presentation, January 28, 2015 (hereafter referred to as the Lab Presentation 2015 ) $ Maternal dazap2 regulates germ granule formation in zebrafish primordial germ cells. Presented at the Germ Cells, Cold Spring Harbor, NY, October 2014, NYC-Wide Stem Cell Event, Stem Cells in the City, NY, November 2014, Mid-Atlantic Regional Zebrafish Meeting, PA, November 2014, and New York Metropolitan Zebrafish Meeting, Cornell, NY, January 2015 (hereafter referred to as Poster 1, 2014-2015 ) $ Cytoskeleton, microtubules, centrosomes, germline cyst, Bucky ball, oocytes. Poster presented at the Mid-Atlantic Regional Zebrafish Meeting, Bronx, NY, July 2015 (hereafter referred to as MARZ 2015 ) 2

$ Bucky ball associates with the centrosome and promotes microtubule cytoskeleton rearrangements to establish oocyte polarity in zebrafish. Poster presented at the American Society for Cell Biology (ASCB) Meeting, San Diego, CA, December 2015 (hereafter referred to as ACSB 2015 ) ORI found that Respondent intentionally falsified and/or fabricated data for germ-cell development in zebrafish Dazap2 maternal-effect mutants (MDazap2) in one (1) paper and two (2) presentations when the mutants were not produced nor the data derived from them. Specifically, Respondent: falsified thirty-eight (38) fluorescent image panels by drawing staining in PhotoShop and falsely labeling them in Figures 1F, 1G, 2A, 2C, 2E, 2F, 2G, 3A, 3D, 4A, and S2A in the Cell Reports paper and included some of the same images in seven (7) figures in Lab Presentation 2015 and in six (6) figures in Poster 1 2014-2015 fabricated numbers for data presented in ten (10) graphs in Figures 1L, 2B, 2D, 2H, 3B, 4B, 4C, S2B, S2C, and S3B in the Cell Reports paper and included some of the same graphs in seven (7) figures in Lab Presentation 2015 and in six (6) figures in Poster 1 2014-2015 3

ORI found that Respondent intentionally fabricated and/or falsified data for zebrafish embryogenesis and oocyte polarity in two (2) papers and two (2) presentations when the data were not obtained from actual experiments. Specifically, Respondent: $ falsified twenty-four (24) fluorescent image panels by drawing staining in Photoshop and falsely labeling them in Figures 5B, 5C, 5D, 5E, 7A, 7B, 7D, 8A, 8B, 9A, and 9B in the August 2015 Development paper and included some of the same images in four (4) figures in the ASCB 2015 poster and in two (2) figures in the MARZ 2015 poster $ fabricated numbers for data presented in eight (8) graphs and one (1) illustration in Figures 5F, 7C, 7E, 8C, 8F-I, 9C, and 9D in the December 2015 Development paper and Figure 2F in the August 2015 Development paper and included some of the same graphs in four (4) figures in the ASCB 2015 poster and in two (2) figures in the MARZ 2015 poster Ms. Forbes has entered into a Voluntary Exclusion Agreement (Agreement) and has voluntarily agreed for a period of three (3) years, beginning on May 6, 2016: (1) to exclude herself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as covered transactions 4

pursuant to HHS Implementation (2 C.F.R. Part 376 et seq) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 C.F.R. Part 180 (collectively the Debarment Regulations ); (2) that she will neither apply for nor permit her name to be used on any application, proposal, or other request for funds to the United States Government or any of its agencies, as defined in the Debarment Regulations; Respondent will further ensure that during the period of the voluntary exclusion, she will neither receive nor be supported by funds of the United States Government and its agencies made available through grants, subgrants, cooperative agreements, contracts, or subcontracts, as discussed in the Debarment Regulations; and (3) to exclude herself from serving in any advisory capacity to the U.S. Public Health Service (PHS) including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: Director Office of Research Integrity 1101 Wootton Parkway, Suite 750 Rockville, MD 20852 (240) 453-8200 Kathryn M. Partin Director Office of Research Integrity 5

[FR Doc. 2016-13541 Filed: 6/7/2016 8:45 am; Publication Date: 6/8/2016] 6